Filtered By:
Condition: Ischemic Stroke
Drug: Clopidogrel

This page shows you your search results in order of relevance. This is page number 12.

Order by Relevance | Date

Total 1287 results found since Jan 2013.

Associations of CYP2C19 and F2R genetic polymorphisms with platelet reactivity in Chinese ischemic stroke patients receiving clopidogrel therapy
Conclusions Together, these results emphasized the necessity of genotype-directed antiplatelet therapy and facilitated to minimize adverse ischemic events.
Source: Pharmacogenetics and Genomics - May 13, 2022 Category: Genetics & Stem Cells Tags: Original Articles Source Type: research

No rebound effect after a course of clopidogrel in patients with acute TIA or minor stroke
CONCLUSIONS: No rebound increase in the risk of ischemic stroke and composite events was found during the 90 days after discontinuation of clopidogrel therapy in patients with TIA or minor stroke in the CHANCE trial.TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00979589.PMID:35695332 | DOI:10.1080/01616412.2022.2075660
Source: Neurological Research - June 13, 2022 Category: Neurology Authors: Xinmiao Zhang Jing Jing Xingquan Zhao Liping Liu Anxin Wang Yuesong Pan David Wang S Claiborne Johnston Yilong Wang Yongjun Wang Xia Meng Source Type: research

Sex Difference in the Impact of Dual Antiplatelet Therapy using Cilostazol for Secondary Stroke Prevention: A Sub-Analysis of CSPS.com
CONCLUSIONS: Long-term DAPT using cilostazol reduced the recurrence of ischemic stroke and prolonged the recurrence-free time in male patients, but not in female patients.PMID:36070920 | DOI:10.5551/jat.63660
Source: Journal of Atherosclerosis and Thrombosis - September 7, 2022 Category: Cardiology Authors: Haruhiko Hoshino Kazunori Toyoda Katsuhiro Omae Kaito Takahashi Shinichiro Uchiyama Kazumi Kimura Keiji Yamaguchi Kazuo Minematsu Hideki Origasa Takenori Yamaguchi CSPS.com Trial Investigators Source Type: research

Evaluation and subgroup analysis of the efficacy and safety of intensive rosuvastatin therapy combined with dual antiplatelet therapy in patients with acute ischemic stroke
ConclusionsWithout increasing bleeding and statin-associated adverse events, intensive rosuvastatin therapy plus 7-day DAPT significantly reduced the risk of recurrent stroke, especially for subgroups with high-risk factors.Clinical trial registration. China Clinical Trial Registration Center (ChiCTR1800017809).
Source: European Journal of Clinical Pharmacology - December 29, 2022 Category: Drugs & Pharmacology Source Type: research